The global biosimilars market is set for significant expansion in 2025, projected to reach between USD 21.95 billion and USD 42.53 billion.
The European Commission has approved AstraZeneca’s Imfinzi, establishing a new standard of care for muscle-invasive bladder cancer. This landmark decision makes Imfinzi the first perioperative immunotherapy available to patients in the EU, following a pivotal Phase III trial where the regimen significantly reduced the risk of cancer recurrence and death. This approval marks a transformative moment for patients with this high-risk disease.
Semaglutide has transformed obesity and diabetes care, offering significant weight loss and glucose control with once-weekly dosing. Here’s a look at its clinical promise and expanding role in medicine.
Chronic pain is a crippling illness that significantly lowers quality of life and frequently results in a dependence on opioid drugs, which have serious adverse [Read More…]
Pfizer announces its hemophilia drug HYMPAVZIâ„¢ significantly reduced annualized bleeding rates in its Phase 3 BASIS study for patients with inhibitors.
A significant step in Alzheimer’s care: The FDA’s updated approval for the Amyvid PET scan allows for better diagnosis and patient selection for the latest amyloid-based treatments
AstraZeneca’s Datroway has received US FDA approval for advanced EGFR-mutated lung cancer. This first-in-class TROP2-directed therapy offers a vital new option for patients who have exhausted previous treatments.
Novo Nordisk announced that its leading diabetes medication, Ozempic® (semaglutide), has received a positive recommendation in the EU for an updated label to include peripheral arterial disease.
Amgen presented Phase 2 data showing that its investigational obesity therapy, maritide, administered monthly, led to significant weight loss in adults with obesity or overweight. The treatment was generally well tolerated, supporting further clinical development.
Eli Lilly’s once-weekly insulin, efsitora alfa, has shown promising results in Phase 3 clinical trials. The innovative treatment demonstrated A1C reductions comparable to daily basal insulins, with a consistent safety profile.
